#1 Clinical Trials Search in Europe

Islatravir

Islatravir, also known as MK-8591, is an investigational drug being studied for its potential in treating and preventing HIV-1 infection. This article summarizes key findings from various clinical trials examining Islatravir’s safety, efficacy, and pharmacokinetics in different populations and dosing regimens.

Table of Contents

What is Islatravir?

Islatravir, also known as MK-8591, is a new medication being developed for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection[1]. It belongs to a class of drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs), which work in a unique way to fight HIV[2].

How Islatravir Works

Islatravir works by interfering with the HIV virus’s ability to replicate itself in the body. It does this by blocking an enzyme called reverse transcriptase, which the virus needs to make copies of itself[1]. What makes Islatravir unique is that it stays active in the body for a long time, which may allow for less frequent dosing compared to other HIV medications[3].

Conditions Treated by Islatravir

Islatravir is being studied for two main purposes:

  • Treatment of HIV-1 infection: It’s being tested in people who have HIV but haven’t taken HIV medications before (treatment-naïve patients)[2].
  • Prevention of HIV infection: It’s also being studied as a potential medication to prevent HIV in people who are at risk of getting the virus[3].

Dosage and Administration

Islatravir is being studied in various forms and dosages:

  • Oral tablets: Doses ranging from 0.25 mg to 60 mg have been tested, taken once daily or once monthly[4][3].
  • Implants: An implantable form that releases the drug slowly over time is also being studied[5].
  • Combination therapy: Islatravir is often studied in combination with other HIV drugs like doravirine and lamivudine[2].

Clinical Trials and Research

Islatravir is currently in various stages of clinical trials. These studies are designed to test its safety, how well it works, and how the body processes it (pharmacokinetics). Some key findings from these trials include:

  • Islatravir has shown promising results in reducing HIV levels in the blood[1].
  • It may be effective when taken less frequently than current HIV medications, potentially improving treatment adherence[3].
  • Studies are ongoing to determine the best dose and combination with other HIV drugs[2].

Potential Side Effects

As with all medications, Islatravir may cause side effects. In clinical trials, researchers closely monitor for any adverse events (AEs). Common side effects reported in studies include:

  • Headache
  • Nausea
  • Diarrhea
  • Fatigue

It’s important to note that the full side effect profile is still being studied, and more information will become available as research progresses[3][2].

Use in Special Populations

Researchers are also studying how Islatravir works in different groups of people:

  • People with kidney problems: A study is looking at how the drug is processed in people with severe kidney impairment[6].
  • People with liver problems: Another study is examining the drug’s effects in people with moderate liver impairment[7].
  • Transgender and gender diverse individuals: A study is evaluating the safety and effectiveness of Islatravir in people receiving gender-affirming hormone therapy[4].

Future Developments

Islatravir is still in the research phase and is not yet approved for general use. However, ongoing studies are exploring its potential in various forms:

  • Long-acting oral formulations: Researchers are studying whether Islatravir could be taken once a month instead of daily[3].
  • Implants: An implantable form that could provide HIV prevention for extended periods is being investigated[5].
  • Combination therapies: Studies are ongoing to find the best combination of Islatravir with other HIV drugs for both treatment and prevention[2][8].

As research continues, more information about Islatravir’s effectiveness, safety, and potential uses will become available. It’s important for patients to discuss any questions or concerns about HIV treatment or prevention with their healthcare provider.

Aspect Details
Study Populations Healthy adults, HIV-1 infected individuals, people with renal or hepatic impairment, transgender and gender diverse individuals
Dosage Forms Oral tablets/capsules (daily and monthly), implantable device
Dosage Strengths Ranging from 0.25 mg to 120 mg, depending on the study
Primary Outcomes Safety, tolerability, pharmacokinetics, antiviral activity
Key Measurements Adverse events, drug concentrations in plasma and cells, HIV-1 RNA levels
Special Considerations Drug interactions (e.g., with methadone), effect of food on absorption, use in combination with other antiretroviral drugs
Potential Applications HIV-1 treatment, pre-exposure prophylaxis (PrEP)

FAQ

  • What is Islatravir? Islatravir (also known as MK-8591) is an investigational drug being studied for its potential in treating and preventing HIV-1 infection. It is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) that is being evaluated in various clinical trials.
  • How is Islatravir administered? Islatravir has been studied in various forms of administration, including oral tablets or capsules taken daily or monthly, and as an implantable device. The dosage and frequency depend on the specific clinical trial and intended use (treatment or prevention).
  • What populations have been included in Islatravir clinical trials? Clinical trials have included diverse populations such as healthy adults, individuals with HIV-1 infection, people with renal or hepatic impairment, and transgender and gender diverse individuals. Some studies have also focused on people at low risk for HIV-1 infection to evaluate its potential as a preventive measure.
  • What are the main outcomes being studied in Islatravir trials? The main outcomes being studied include safety and tolerability, pharmacokinetics (how the drug moves through the body), and in some cases, antiviral activity. Researchers are measuring factors such as adverse events, drug concentrations in plasma and cells, and changes in HIV-1 RNA levels.
  • Are there any notable side effects or safety concerns with Islatravir? While safety is a primary focus of these trials, specific side effects are not detailed in the provided summaries. The studies are designed to monitor for adverse events, including serious adverse events, and any events leading to discontinuation of the drug. More detailed safety information would be available in the full results of each trial.

Ongoing Clinical Trials on Islatravir

  • A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

    Recruiting

    1 1 1
    Investigated drugs:
    France Spain

  • Study on Switching to Doravirine and Islatravir for People with HIV-1 on Antiretroviral Therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Finland France Germany Italy Poland Spain

  • Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study to Compare Weekly Islatravir/Lenacapavir with Bictegravir/Emtricitabine/Tenofovir in People with HIV-1 Who Are Virologically Suppressed

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Spain

  • Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Spain

  • Study on Switching to Islatravir and MK-8507 for Adults with HIV-1 Who Are Virologically Suppressed on a Drug Combination

    Not recruiting

    1 1
    Investigated drugs:
    France

  • Study on the Safety of Doravirine and Islatravir for HIV Patients Who Previously Participated in Doravirine/Islatravir Trials

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy

Glossary

  • Islatravir: An investigational drug (also known as MK-8591) being studied for HIV-1 treatment and prevention. It is a nucleoside reverse transcriptase translocation inhibitor (NRTTI).
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, calculated from a graph of drug concentration in the blood versus time.
  • Maximum Concentration (Cmax): The highest concentration of a drug observed in the blood after administration.
  • Half-life (t1/2): The time it takes for the concentration of a drug in the body to decrease by half.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or is otherwise medically significant.
  • HIV-1 RNA: The genetic material of HIV-1, often measured to determine the amount of virus in a person's blood (viral load).
  • Peripheral Blood Mononuclear Cells (PBMC): A type of blood cell with a round nucleus, including lymphocytes and monocytes, which are important in the immune system and can be infected by HIV.
  • Gender-affirming Hormone Therapy (GAHT): The use of hormones to align a person's physical characteristics with their gender identity, often used by transgender and gender diverse individuals.

References

  1. https://clinicaltrials.gov/study/NCT02217904
  2. https://clinicaltrials.gov/study/NCT03272347
  3. https://clinicaltrials.gov/study/NCT04003103
  4. https://clinicaltrials.gov/study/NCT05130086
  5. https://clinicaltrials.gov/study/NCT05115838
  6. https://clinicaltrials.gov/study/NCT04303156
  7. https://clinicaltrials.gov/study/NCT04515641
  8. https://clinicaltrials.gov/study/NCT06719570